Altimmune, Inc., a biopharmaceutical company, has announced its 2024 Annual Meeting of Stockholders to be held virtually on September 26, 2024. The meeting will include the election of eight directors, the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, and an advisory vote on executive compensation. Stockholders are invited to attend the meeting online, vote electronically, and submit questions. The Board of Directors urges stockholders to read the attached Proxy Statement carefully and vote on the proposals outlined. The company's CEO, Vipin K. Garg, Ph.D., expressed gratitude for continued support and emphasized the importance of stockholder votes.

Altimmune, Inc., a biopharmaceutical company, has announced its 2024 Annual Meeting of Stockholders to be held virtually on September 26, 2024. The meeting will include the election of eight directors, the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, and an advisory vote on executive compensation. Stockholders are invited to attend the meeting online, vote electronically, and submit questions. The Board of Directors urges stockholders to read the attached Proxy Statement carefully and vote on the proposals outlined. The company's CEO, Vipin K. Garg, Ph.D., expressed gratitude for continued support and emphasized the importance of stockholder votes.